Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
While net sales declined due to the launch of competing products and changes in market demand, operating income and ordinary income increased as a result of optimized supply pricing, the effects of measures to reduce manufacturing costs, and a decrease in research and development expenses. Net income also increased due to extraordinary gains, including the reversal gain on cancellation of lease agreements.
A description of significant events and conditions is included. Although events and conditions that raise doubts have arisen due to net losses and negative operating cash flow in prior fiscal years, as well as planned research and development investments, the company recognizes that there is no significant uncertainty regarding the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 1,269 Millions of yen (YoY -26.2%) |
| Operating profit | 216 Millions of yen (YoY +17.3%) |
| Ordinary income | 203 Millions of yen (YoY +16.0%) |
| Profit attributable to owners of the parent | 197 Millions of yen (YoY +26.0%) |
| Net income per share | ¥3.99 |
| Equity ratio | End of the current fiscal period 29.4 / End of previous period 26.4 |
| Total assets | 6,130 Millions of yen |
| Net assets | 1,837 Millions of yen |
| Full-year earnings forecast | Net Sales 5,000～6,000 / Operating profit 100～600 / Ordinary income Not disclosed / Net income Not disclosed |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Depreciation and amortization | ¥30 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of non-current assets / Amount ¥636 thousand, Item Gain on reversal of subscription rights to shares / Amount ¥13,294 thousand, Item Reversal gain on cancellation of lease agreements / Amount ¥18,819 thousand, Item Reversal of asset retirement obligations / Amount ¥614 thousand / Total extraordinary income Amount ¥33,364 thousand / Extraordinary loss No |
| Disclosure regarding the going concern assumption | A description of significant events and conditions is included. Although events and conditions that raise doubts have arisen due to net losses and negative operating cash flow in prior fiscal years, as well as planned research and development investments, the company recognizes that there is no significant uncertainty regarding the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | From 1 July to 22 July 2026, the stock acquisition rights attached to the fourth unsecured convertible bonds with stock acquisition rights were exercised. The company issued 946,969 shares of common stock, increasing the total conversion price by ¥125,000 thousand and increasing capital and capital surplus by ¥62,500 thousand each. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 49,636,019 |
| Treasury Shares at Period-End | 144 |
| Factors Behind Changes in Business Performance | While net sales declined due to the launch of competing products and changes in market demand, operating income and ordinary income increased as a result of optimized supply pricing, the effects of measures to reduce manufacturing costs, and a decrease in research and development expenses. Net income also increased due to extraordinary gains, including the reversal gain on cancellation of lease agreements. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales declined due to changes in the competitive environment and market demand for GBS-007 following the launch of an aflibercept biosimilar and its biosimilar authorized generic. On the profit front, although the weaker yen and changes in the product mix affected costs, optimized supply pricing, the effects of measures to reduce manufacturing costs, and a year-on-year decrease in research and development expenses drove profits higher. In addition, extraordinary gains, including the reversal of losses on the cancellation of lease agreements, contributed to net income.